داروی بورسی روی پیشخوان سرمایه؛ نسخه دقیق سرمایه‌گذاری در صنعت دارو

On June 29, in the 16th episode of Watchlist, we hosted Mohammad Taheri, the manager of Pharmacian Fund, to examine one of the most important questions of the market these days about the pharmaceutical industry; an industry that has always been in the spotlight of investors, but now there are possible signs of pressure in production and uncertainty in its outlook. We began the conversation with the question: Given the decline in pharmaceutical industry production, beyond the usual seasonal pattern of decline between March and April, how should this decline be interpreted in the industry's outlook this year? Is this decline simply a temporary and recurring fluctuation, or could it be a sign of deeper pressures on the performance of pharmaceutical companies? The discussion then turned to how these developments will affect the investment outlook in the pharmaceutical industry. Is this industry still valuable, as can be seen from the buying lines these days? And if the answer is yes, where is the best time and best entry point to invest in this group? In this section, in addition to examining investment opportunities, we also address the risks facing the pharmaceutical industry; from production and supply issues to policy challenges, pricing and the quality of companies' profitability. If you want to know what the investment watchlist in the pharmaceutical industry should be based on, don't miss this section. Website fardayeeghtesad.com Instagram instagram.com/farda_eghtesad Twitter twitter.com/feghtesad Telegram t.me/feghtesad